THERANOSTICS ECOSYSTEM FOR PERSONALISED CARE

HealthHORIZON-JU-RIAID: 101172788
EC Contribution
โ‚ฌ141,310
Consortium Size
30 orgs
Start Year
2024
โ–ถSummary

Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry partners, European and medical societies focusing on training and education, a patient advocacy group spearheaded by an experienced project management group. Thera4Care aims to establish a European network of radiotheranostics centres able to rapidly develop and implement radiotheranostics tools and solutions to drive precision health. The overarching vision of Thera4Care is to revolutionise radiotheranostics procedures by establishing, implementing, and disseminating standardised scalable methods to produce and efficiently administer key radiotheranostics solutions. Thera4Care focus is on developing diagnostic and therapeutic ligands tailored to key disease areas (such as solid tumours), aligning with the growing significance of multi-modal radiotheranostics solutions dominated by radionuclide-based therapy and companion diagnostics. Thera4Care project is scheduled for 5 years and consists of 9 work packages. WP1 handles Project Management, WP2 focuses on Regulatory aspects, WP3 plans Preclinical studies, WP4 provides Supply chain, WP5 develops Clinical Trials, WP6 generates AI models, WP7 focuses on Dosimetry, WP8 develops Precision Imaging components, while WP9 focuses on Education and Dissemination.โ€ฏ Thera4Care will advocate for the progress of radiotheranostics, with the goal of increasing medical knowledge and enhancing treatment efficacy for improved patient outcomes. Concurrently, aims to coordinate scientific initiatives across European landscapes, leveraging a comprehensive and multimodal approach to cancer therapy applicable to various cancer types. Lastly, will work on the establishment of sustainable supply and production networks and the upscaling of production methodologies and supply chains across the public and private sectors, to enhance the availability of radionuclides.

Consortium (30)

๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA CATTOLICA DEL SACRO CUOREIT
coordinator
๐Ÿ‡ซ๐Ÿ‡ฎ AIFORIA TECHNOLOGIES OYJFI
partner
๐Ÿ‡ง๐Ÿ‡ช ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE JULES BORDETBE
partner
๐Ÿ‡ธ๐Ÿ‡ช ATLEY SOLUTIONS ABSE
partner
๐Ÿ‡ฉ๐Ÿ‡ช COLLABORATE PROJECT MANAGEMENT UG HAFTUNGSBESCHRANKTDE
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ CURASIGHT ASDK
partner
๐Ÿ‡ฎ๐Ÿ‡น DATAWIZARD SRLIT
partner
๐Ÿ‡ซ๐Ÿ‡ท DOSISOFTFR
partner
๐Ÿ‡ณ๐Ÿ‡ฑ ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMNL
partner
๐Ÿ‡ฆ๐Ÿ‡น EUROPEAN ASSOCIATION OF NUCLEAR MEDICINEAT
partner
๐Ÿ‡ธ๐Ÿ‡ช EXINI DIAGNOSTICS ABSE
partner
๐Ÿ‡ฎ๐Ÿ‡น Fondazione Policlinico Universitario Agostino Gemelli IRCCSIT
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANONES
partner
๐Ÿ‡บ๐Ÿ‡ธ GE Healthcare IITS USA Corp.US
partner
๐Ÿ‡ฌ๐Ÿ‡ง GE HEALTHCARE LIMITEDGB
partner
๐Ÿ‡ญ๐Ÿ‡บ GE HEALTHCARE MAGYARORSZAG KFTHU
partner
๐Ÿ‡ฎ๐Ÿ‡ฑ GE MEDICAL SYSTEMS ISRAEL LTDIL
partner
๐Ÿ‡ธ๐Ÿ‡ช GEMS PET SYSTEMS AKTIEBOLAGSE
partner
๐Ÿ‡ธ๐Ÿ‡ช GOETEBORGS UNIVERSITETSE
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT DE CANCEROLOGIE DE L'OUESTFR
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ MINERVA IMAGING APSDK
partner
๐Ÿ‡จ๐Ÿ‡ญ PAUL SCHERRER INSTITUTCH
partner
๐Ÿ‡บ๐Ÿ‡ธ PERSPECTIVE THERAPEUTICS INCUS
partner
๐Ÿ‡ญ๐Ÿ‡บ SEMMELWEIS EGYETEMHU
partner
๐Ÿ‡ช๐Ÿ‡ธ SERVICIO MADRILENO DE SALUDES
partner
๐Ÿ‡ง๐Ÿ‡ช STUDIECENTRUM VOOR KERNENERGIE / CENTRE D'ETUDE DE L'ENERGIE NUCLEAIREBE
partner
๐Ÿ‡ญ๐Ÿ‡บ SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAGHU
partner
๐Ÿ‡ณ๐Ÿ‡ฑ TERTHERA B.V.NL
partner
๐Ÿ‡ง๐Ÿ‡ช THE ONCIDIUM FOUNDATIONBE
partner
๐Ÿ‡ฉ๐Ÿ‡ช UNIVERSITAETSKLINIKUM ESSENDE
partner